Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

Blood

Volumn 107, Issue 9, 2006, Pages 3492-3494

  Miyakoshi, Shigesaburo ^a   Kami, Masahiro ^b   Yuji, Koichiro ^b   Matsumura, Tomoko ^b   Takatoku, Masaaki ^b   Sasaki, Makoto ^b   Narimatsu, Hiroto ^b   Fujii, Takeshi ^b   Kawabata, Masateru ^b   Taniguchi, Shuichi ^b   Ozawa, Keiya ^b   Oshimi, Kazuo ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; METHYLPREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; ETHNIC DIFFERENCE; EUROPE; FEMALE; HUMAN; JAPAN; LUNG EDEMA; LUNG INFILTRATE; LUNG INJURY; MULTIPLE MYELOMA; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY FAILURE; UNITED STATES; WHEEZING;

EID: 33645292701     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4541     Document Type: Article

References (17)

1. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165-172.
2. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
4. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer. 2005;103:2584-2589.
5. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
6. Lara PN Jr, Davies AM, Mack PC, et al. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004;31:40-46.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
8. Kusumi E, Kami M, Yuji K, et al. Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor. Bone Marrow Transplant. 2004;33:697-702.
9. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954-3964.
10. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005;33:1723-1728.
11. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630-639.
12. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005;45:465-476.
13. Ankermann T, Reisner A, Wiemann T, Krams M, Kohler H, Krause MF. Topical inhibition of nuclear factor-kappaB enhances reduction in lung edema by surfactant in a piglet model of airway lavage. Crit Care Med. 2005;33:1384-1391.
14. Moine P, McIntyre R, Schwartz MD, et al. NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock. 2000;13:85-91.
15. Verleden GM, du Bois RM, Bouros D, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J Suppl. 2001;32:17s-29s.
16. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28:103-113.
17. Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201-1204.